1
|
Poizeau F, Maruani A, Staumont-Sallé D, Jouan N, Ly S, Schollhammer M, Reverte M, Dibao-Dina C, Duong TA, Matard B, Penso-Assathiany D, Dupuy A, Carriot M, Seï JF, Corgibet F, Guillot B, Barbarot S, Leducq S, Bertolotti A, Tannous J, Chaby G, Jullien D, Pépin E, Quéreux G, Beylot-Barry M, Chosidow O. Promoting clinical research in community-based practice: Threats and opportunities. Ann Dermatol Venereol 2024; 151:103272. [PMID: 38688174 DOI: 10.1016/j.annder.2024.103272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/12/2023] [Accepted: 03/04/2024] [Indexed: 05/02/2024]
Affiliation(s)
- F Poizeau
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France.
| | - A Maruani
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHRU de Tours, Service de Dermatologie, Unité de Dermatologie pédiatrique, 37000 Tours, France; Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France
| | - D Staumont-Sallé
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | - N Jouan
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Cabinet de Dermatologie, 29200 Brest, France
| | - S Ly
- Cabinet de Dermatologie, Gradignan, France; Service de Dermatologie, Hôpital St André, Bordeaux, France
| | - M Schollhammer
- Cabinet de Dermatologie, 29200 Brest, France; Service de Dermatologie, CHU Brest, Brest, France
| | - M Reverte
- Cabinet de Dermatologie, 83120 Sainte-Maxime, France
| | - C Dibao-Dina
- Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France; Département Universitaire de Médecine Générale, Université de Tours, Tours, France
| | - T-A Duong
- Service de dermatologie générale et oncologique, CHU Ambroise Paré, Boulogne-Billancourt, France
| | - B Matard
- Centre Sabouraud, Hôpital Saint Louis, Paris, France
| | | | - A Dupuy
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France
| | - M Carriot
- Infirmière puéricultrice de recherche, CIC 1415 de Tours, Tours, France
| | - J-F Seï
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Fédération Française de Formation Continue et d'Évaluation en Dermatologie Vénéréologie
| | - F Corgibet
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - B Guillot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, Université de Montpellier, Montpellier, France
| | - S Barbarot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Nantes Université, Service de Dermatologie, CHU Nantes, INRAE, UMR 1280, PhAN, F-44000 Nantes, France
| | - S Leducq
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHRU Tours, 37000 Tours, France
| | - A Bertolotti
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CIC-INSERM1410, Service de Maladies Infectieuses - Dermatologie, CHU de la Réunion, Saint Pierre, La Réunion, France
| | - J Tannous
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - G Chaby
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Amiens, 80000 Amiens, France
| | - D Jullien
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Lyon F-69003; Université Lyon-1, INSERM Unité 1111-CIRI, Lyon F-69007, France
| | - E Pépin
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, FFFCEDV, Villepreux, France
| | - G Quéreux
- Service de Dermatologie, CHU Nantes, Université de Nantes, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, F-44000 Nantes, France
| | - M Beylot-Barry
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, INSERM U1312, Bordeaux Institute of Oncology, Univ Bordeaux, Bordeaux, France
| | - O Chosidow
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, consultation dermatoses faciales, Paris, France
| |
Collapse
|
2
|
Skrek S, Di Lernia V, Beauchet A, Bursztejn AC, Belloni Fortina A, Lesiak A, Thomas J, Brzezinski P, Topkarci Z, Murashkin N, Torres T, Epishev R, Chiriac A, McPherson T, Akinde M, Maruani A, Luna PC, Vidaurri de la Cruz H, Mallet S, Leducq S, Sergeant M, Zitouni J, Mahil SK, Smith CH, Flohr C, Bachelez H, Mahé E. Clinical and epidemiological features of psoriasis exacerbations in children with SARS-CoV-2 infection. J Eur Acad Dermatol Venereol 2023; 37:e1192-e1195. [PMID: 37326146 DOI: 10.1111/jdv.19261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 06/13/2023] [Indexed: 06/17/2023]
Affiliation(s)
- S Skrek
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - V Di Lernia
- Dermatology Unit, Arcispedale S. Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - A Beauchet
- Department of Public Health, Hôpital Raymond Poincaré, Garches, France
| | - A-C Bursztejn
- Department of Dermatology, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - A Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
| | - A Lesiak
- Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
| | - J Thomas
- J. T. Skin Care Centre, Chennai, India
| | - P Brzezinski
- Department of Dermatology, Voivodship Specialist Hospital in Slupsk, Slupsk, Poland
| | - Z Topkarci
- Department of Dermatology, Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - N Murashkin
- Department of Dermatology, Federal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - R Epishev
- Department of Dermatology, Federal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - A Chiriac
- Department of Dermatology, Nicolina Medical Center, P. Poni Institute of Macromolecular Chemistry, Romanian Academy, Iași, Romania
| | - T McPherson
- Department of Dermatology, Oxford University Hospitals NHS Trust, Oxford, UK
| | - M Akinde
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Maruani
- Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE - CHRU Tours, Tours, France
| | - P C Luna
- Department of Dermatology, Hospital Alemán, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - H Vidaurri de la Cruz
- Servicio de Dermatología Pediátrica, Hospital General de México Dr. Eduardo Liceaga, Secretaría de Salud, Ciudad de México, Mexico
| | - S Mallet
- Department of Dermatology, Hôpital de la Timone, Assistance-Publique-Hôpitaux de Marseille, Marseille, France
| | - S Leducq
- Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE - CHRU Tours, Tours, France
| | - M Sergeant
- Department of Dermatology, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - J Zitouni
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S K Mahil
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - C H Smith
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Flohr
- Department of Dermatology, Oxford University Hospitals NHS Trust, Oxford, UK
| | - H Bachelez
- Department of Dermatology, Hôpital Saint-Louis, AP-HP, Paris, France
- Laboratory of Genetic Skin Diseases, INSERM U1163, Imagine Institute, Université de Paris, Paris, France
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| |
Collapse
|
3
|
Mauguen C, Maruani A, Barbarot S, Abasq C, Martin L, Herbert J, Goronflot T, Gourraud PA, Happe A, Descatha A, Chrétien JM, Beuchée A, Adamski H, Dupuy A, Bouzillé G, Oger E, Droitcourt C. Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub. Ann Dermatol Venereol 2023; 150:189-194. [PMID: 37225615 DOI: 10.1016/j.annder.2023.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 12/08/2022] [Accepted: 03/24/2023] [Indexed: 05/26/2023]
Abstract
BACKGROUND The factors associated with early relapse of infantile haemangioma (IH) after a first course of treatment with oral propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated. OBJECTIVES To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines. METHODS We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database. All children treated for at least 6 months with oral propranolol for IH between 31 June 2014 and 31 December 2021, and with a follow-up visit at least three months after treatment discontinuation were included. A case was defined as relapse of IH within three months of treatment discontinuation; each case was matched for age at treatment initiation and for centre, with four (relapse-free) controls. The association between relapse and treatment or IH characteristics was expressed as an odds ratio (OR) from univariate and multivariate conditional logistic regressions. RESULTS A total of 225 children were included. Of these, 36 (16%) relapsed early. In a multivariate analysis, a deep IH component was a risk factor for early relapse [OR = 8.93; 95%CI: 1.0-78.9, p = 0.05]. A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0.11; 95%CI: 0.02-0.7, p = 0.02]. Tapering before propranolol discontinuation was not associated with a lower risk of early relapse. CONCLUSION The risk factors for late and early relapse are probably different. Investigation of the risk factors for early vs. late IH relapse is now warranted.
Collapse
Affiliation(s)
- C Mauguen
- Department of Dermatology, CHU Rennes, 35000 Rennes, France.
| | - A Maruani
- University of Tours, INSERM 1246-SPHERE, Department of Dermatology, Tours University Hospital, F-37000 Tours, France; Dermatology Department and Reference Centre for Rare Diseases and Vascular Malformations (MAGEC), Tours University Hospital, 37000 Tours, France
| | - S Barbarot
- Department of Dermatology, CHU Nantes and INSERM CIC 004, 44000 Nantes, France
| | - C Abasq
- Department of Dermatology, Brest University Hospital, 29200 Brest, France
| | - L Martin
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - J Herbert
- Clinical Data Centre, Public Health and Prevention Unit, Tours University Hospital, 37044 Tours, France
| | - T Goronflot
- Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, 44000 Nantes, France
| | - P-A Gourraud
- Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, 44000 Nantes, France
| | - A Happe
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - A Descatha
- Univ Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 49000 Angers, France
| | - J-M Chrétien
- Clinical Research Department, Angers University Hospital, 49000 Angers, France
| | - A Beuchée
- Department of Neonatalogy, Rennes University Hospital, Rennes, France
| | - H Adamski
- Department of Dermatology, CHU Rennes, 35000 Rennes, France
| | - A Dupuy
- Department of Dermatology, CHU Rennes, 35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - G Bouzillé
- Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, 35000 Rennes, France
| | - E Oger
- Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, 35000 Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, 35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| |
Collapse
|
4
|
van Eeghen AM, Stemkens D, Fernández-Fructuoso JR, Maruani A, Hadzsiev K, Gaasterland CMW, Klein Haneveld MJ, Vyshka K, Hugon A, van Eeghen AM, van Balkom IDC. Consensus recommendations on organization of care for individuals with Phelan-McDermid syndrome. Eur J Med Genet 2023:104747. [PMID: 37003574 DOI: 10.1016/j.ejmg.2023.104747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 03/05/2023] [Accepted: 03/18/2023] [Indexed: 04/03/2023]
Abstract
The manifestations of Phelan-McDermid syndrome (PMS) are complex, warranting expert and multidisciplinary care in all life stages. In the present paper we propose consensus recommendations on the organization of care for individuals with PMS. We indicate that care should consider all life domains, which can be done within the framework of the International Classification of Functioning, Disability and Health (ICF). This framework assesses disability and functioning as the outcome of the individual's interactions with other factors. The different roles within care, such as performed by a centre of expertise, by regional health care providers and by a coordinating physician are addressed. A surveillance scheme and emergency card is provided and disciplines participating in a multidisciplinary team for PMS are described. Additionally, recommendations are provided for transition from paediatric to adult care. This care proposition may also be useful for individuals with other rare genetic neurodevelopmental disorders.
Collapse
Affiliation(s)
- A M van Eeghen
- Emma Center for Personalized Medicine, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands; Advisium, 's Heeren Loo, Amersfoort, Netherlands.
| | - D Stemkens
- VSOP - National Patient Alliance for Rare and Genetic Diseases, Soest, the Netherlands
| | | | - A Maruani
- Excellence Center for Autism Spectrum & Neurodevelopmental Disorders, Inovand, Child and Adolescent Psychiatry Department, Hôpital Robert Debre, APHP, Paris, France; CRMR DICR, Rare Disease Center for Intellectual Disabilities, Defiscience, France
| | - K Hadzsiev
- Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary
| | - C M W Gaasterland
- Emma Center for Personalized Medicine, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - M J Klein Haneveld
- Emma Center for Personalized Medicine, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Klea Vyshka
- University Hospital Robert Debre, Paris, France
| | - A Hugon
- University Hospital Robert Debre, Paris, France
| | - A M van Eeghen
- Emma Center for Personalized Medicine, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands; Advisium, 's Heeren Loo, Amersfoort, Netherlands
| | - I D C van Balkom
- Jonx, Department of (Youth) Mental Health and Autism, Lentis Psychiatric Institute, Groningen, Netherlands; Rob Giel Research Centre, Department of Psychiatry, University Medical Center Groningen, Groningen, Netherlands
| |
Collapse
|
5
|
Tabet A, Mahé E, Boralevi F, Maruani A, Hesse S, Gentile S, Mallet S. Herpes zoster in children during the COVID-19 pandemic in France: A retrospective multicenter observational study. Ann Dermatol Venereol 2023; 150:46-48. [PMID: 36813638 PMCID: PMC9940797 DOI: 10.1016/j.annder.2022.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 05/21/2022] [Accepted: 08/30/2022] [Indexed: 02/22/2023]
Affiliation(s)
- A Tabet
- APHM, Aix-Marseille Université, 27, boulevard Jean-Moulin, 13385 Marseille, France.
| | - E Mahé
- Service de Dermatologie, CH Victor Dupouy, 69 Rue du Lieutenant-Colonel Prudhon, 95107 Argenteuil, France
| | - F Boralevi
- Université de Bordeaux, Unité de Dermatologie Pédiatrique, CHU Pellegrin Enfants, place Amélie Raba Léon, 33000 Bordeaux, France
| | - A Maruani
- Universités de Tours et Nantes, SPHERE-INSERM 1246, Service de Dermatologie et Unité de Dermatologie Pédiatrique, CHRU de Tours, 37044 Tours Cedex 9, France
| | - S Hesse
- Aix-Marseille Université, Service de Dermatologie, CHU Timone, 264 Rue Saint-Pierre, 13005 Marseille, France
| | - S Gentile
- Aix-Marseille Université, School of Medicine, La Timone, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Service d'Evaluation Médicale, CHU Conception, 147 boulevard Baille, 13005 Marseille, France
| | - S Mallet
- Aix-Marseille Université, Service de Dermatologie, CHU Timone, 264 Rue Saint-Pierre, 13005 Marseille, France
| |
Collapse
|
6
|
Mahé E, Werner A, Cret L, Salinier C, Guellich A, Maruani A, Assathiany R. Therapeutic inertia during isotretinoin treatment of juvenile acne by dermatologists, paediatricians and general practitioners. Ann Dermatol Venereol 2023; 150:39-45. [PMID: 36642678 DOI: 10.1016/j.annder.2022.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 09/28/2022] [Accepted: 11/08/2022] [Indexed: 01/15/2023]
Abstract
BACKGROUND Isotretinoin is an effective treatment for severe juvenile acne, but it appears to be underused in relation to the recommendations. Therapeutic inertia is defined as a failure to initiate or intensify treatment even when warranted by the recommendations. The aim of this study was to investigate therapeutic inertia among dermatologists (D), paediatricians (P), and general practitioners (GPs) in initiating isotretinoin for moderate-to-very severe juvenile acne. METHODS Data were collected using a questionnaire distributed to French physicians through medical societies via Internet. The questions explored the role in inertia of factors related to physicians, patients, parents, and the healthcare system, and evaluated barriers and facilitators to prescribing isotretinoin. RESULTS In all, 768 physicians responded to the survey (528 D, 178P, and 61 GPs; mean age: 51 years; women: 78 %). Their responses revealed that 99 % of dermatologists felt comfortable prescribing isotretinoin, compared with 8 % and 15 % of paediatricians and GPs (p < 0.05); 93 % of dermatologists were aware of the current guidelines compared with 37 % of paediatricians and GPs. Under 50 % of the physicians had received training on acne in the previous 3 years, regardless of specialty. The most frequently identified factors for inertia were concerns over the psychological consequences of the treatment in adolescents, exclusive requests from parents, and patient unavailability. Paediatricians reported having insufficient knowledge of current recommendations, a lack of training, and a tendency to anticipate poor compliance. Paediatricians and GPs considered that access to first-time prescriptions and peer-to-peer exchanges would constitute facilitating factors in their use of isotretinoin. DISCUSSION Concerns over the psychiatric consequences of isotretinoin in adolescents, the need for frequent follow-up, and lack of continuing medical education were identified as factors favouring inertia in the initiation of isotretinoin treatment in patients with moderate-to-very severe juvenile acne, particularly among paediatricians and GPs. Potential strategies to overcome these barriers include regular training, simplified recommendations in French, and access to first-time prescription for paediatricians and GPs.
Collapse
Affiliation(s)
- E Mahé
- Service de dermatologie et médecine vasculaire, Hôpital Victor-Dupouy, 69 rue du Lieutenant-Colonel-Prud'hon, 95107 Argenteuil, France.
| | - A Werner
- AFPA, 30 rue Emile Zola, 45000 Orléans, France
| | - L Cret
- AFPA, 30 rue Emile Zola, 45000 Orléans, France
| | - C Salinier
- AFPA, 30 rue Emile Zola, 45000 Orléans, France
| | - A Guellich
- Service de dermatologie et médecine vasculaire, Hôpital Victor-Dupouy, 69 rue du Lieutenant-Colonel-Prud'hon, 95107 Argenteuil, France
| | - A Maruani
- Service de dermatologie, Unité de dermatologie pédiatrique, Université de Tours et Nantes, INSERM 1246 SPHERE - CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France
| | | | | |
Collapse
|
7
|
Herbreteau JB, Tavernier E, Joly A, Marchand A, Édée AÉ, Tauveron V, Maruani A. Traditional healers or bonesetters ("rebouteux") in France: A survey of their practice, profile, and customers. Ann Dermatol Venereol 2023:S0151-9638(22)00120-X. [PMID: 36653226 DOI: 10.1016/j.annder.2022.11.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 08/18/2022] [Accepted: 11/17/2022] [Indexed: 01/18/2023]
Abstract
BACKGROUND In France, many people consult "bonesetters" for several medical reasons. Little is known about them. We aimed to investigate the practices of traditional healers in France as well as their profile and that of their customers. METHODS This was a survey carried out in Metropolitan France. A 33-item questionnaire developed by a multidisciplinary group was sent to a sample of 148 traditional healers found on the Internet and by word of mouth. RESULTS Of the 148 questionnaires sent, 89 (60.1 %) were returned and 67 (45.3 %) were analyzed: 51.5 % (n = 34) of respondents were men, and the mean (±standard deviation) age was 51.6 ± 11.6 years. The respondents considered that they had received a gift of healing and were mainly magnetic healers (68.2 %). They became aware of this gift at a mean age of 19.9 ± 14.1 years. The traditional healers practiced mainly in rural areas (54.5 %), at home (59.1 %), and used their hands to transmit energy (95.5 %). They advertised their practice mainly by word of mouth (89.4 %) and had a predominantly female clientele (78.1 %). Various diseases were treated, with the most frequent being subjective complaints (pain, stress, fatigue, insomnia) and dermatological complaints (eczema, accidental and post-herpes-zoster burns, psoriasis, and warts). Most respondents considered their activities to be complementary to conventional medicine, and 10.9 % considered them more effective. Some indicated that they did not consider themselves "healers" but rather "providers of relief". DISCUSSION The results of this survey provide a better understanding of this network of local care that revolves around medicine.
Collapse
Affiliation(s)
| | - E Tavernier
- Universités de Tours et Nantes, INSERM 1246-SPHERE, 37000 Tours, France; Centre Hospitalier Régional Universitaire de Tours, Centre d'Investigation Clinique 1415, 37000 Tours, France
| | - A Joly
- Centre Hospitalier Régional Universitaire de Tours, Service de Chirurgie Maxillo-Faciale et chirurgie plastique et brulés, 37044 Tours Cedex 9, France
| | - A Marchand
- Centre Hospitalier Régional Universitaire de Tours, Service de Dermatologie, Unité de Dermatologie Pédiatrique, 37044 Tours Cedex 9, France
| | - A-É Édée
- Centre Hospitalier Régional Universitaire de Tours, Service de Dermatologie, Unité de Dermatologie Pédiatrique, 37044 Tours Cedex 9, France
| | - V Tauveron
- Centre Hospitalier Régional Universitaire de Tours, Service de Dermatologie, Unité de Dermatologie Pédiatrique, 37044 Tours Cedex 9, France
| | - A Maruani
- Universités de Tours et Nantes, INSERM 1246-SPHERE, 37000 Tours, France; Centre Hospitalier Régional Universitaire de Tours, Service de Dermatologie, Unité de Dermatologie Pédiatrique, 37044 Tours Cedex 9, France.
| |
Collapse
|
8
|
Maruani A, Barbarot S, Gangneux JP, Caseris M, Moreau C, Brun S, Botterel F, Menotti J, Toubiana J, Chouchana L, Beylot-Barry M, Dupin N, Guillot B, Chosidow O. Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: A fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology. Ann Dermatol Venereol 2022; 149:238-240. [PMID: 36229261 DOI: 10.1016/j.annder.2022.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 01/07/2022] [Accepted: 07/12/2022] [Indexed: 11/06/2022]
Affiliation(s)
- A Maruani
- Universités de Tours et Nantes, Inserm 1246-SPHERE, CHRU de Tours, service de dermatologie, unité de dermatologie pédiatrique, 37000 Tours, France; Centre de Preuves en Dermatologie, Société Française de Dermatologie Pédiatrique, Société Française de Dermatologie, France.
| | - S Barbarot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie Pédiatrique, Société Française de Dermatologie, France; Nantes Université, Servie de Dermatologie, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000 Nantes, France
| | - J P Gangneux
- Service de Parasitologie-Mycologie, CHU de Rennes, Univ Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F35000 Rennes, France; Société Française de Mycologie Médicale, France
| | - M Caseris
- Infectiologie mobile, Hôpital Robert Debré, AP-HP, 75019 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie, France
| | - C Moreau
- Service Pharmacie, Hôpital Robert-Debré (AP-HP), 75019 Paris, France
| | - S Brun
- Service de Parasitologie-Mycologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France; Société Française de Mycologie Médicale, France
| | - F Botterel
- Unité de Parasitologie - Mycologie, Département de Prévention, diagnostic et traitement des infections, CHU de Créteil, AP-HP, Université Paris Est Créteil, Créteil, France; Société Française de Mycologie Médicale, France
| | - J Menotti
- Service de Parasitologie et Mycologie Médicale, Institut des Agents Infectieux, Hospices Civils de Lyon / Université Lyon 1, Lyon, France; Société Française de Mycologie Médicale, France
| | - J Toubiana
- Service de pédiatrie générale et maladies infectieuses, Hôpital Necker Enfants malades, AP-HP, Université de Paris, Paris, France
| | - L Chouchana
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, EA 7323 Pharmacologie et Evaluation des Thérapeutiques chez l'enfant et la femme enceinte, Hôpital Cochin, AP-HP, Université de Paris, Paris, France; Société Française de Pharmacologie et Thérapeutique, France
| | - M Beylot-Barry
- Service de Dermatologie, CHU de Bordeaux, INSERM U1312, Bordeaux, France; Centre de Preuves en Dermatologie, Société Française de Dermatologie, France
| | - N Dupin
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, France; Service de dermatologie Hôpital Cochin AP-HP, Paris, France
| | - B Guillot
- Université de Montpellier, Montpellier, France
| | - O Chosidow
- Service de Dermatologie, Hôpitaux Universitaires Henri-Mondor, AP-HP, Créteil, France; Universités de Tours et Nantes, Inserm 1246-SPHERE, France; Centre de Preuves en Dermatologie, GrIDIST Groupe Infectiologie Dermatologique, ISD-SIDA, Société Française de Dermatologie, Paris, France
| |
Collapse
|
9
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Samimi M, Morel B, Caille A, Maruani A, Leducq S. Quality of life of children with capillary malformations of the lower limbs: Evolution and associated factors. Data from the French national paediatric cohort, CONAPE. Ann Dermatol Venereol 2022; 149:271-275. [PMID: 35810006 DOI: 10.1016/j.annder.2022.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 02/16/2022] [Accepted: 03/30/2022] [Indexed: 01/19/2023]
Affiliation(s)
- J Robert
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France
| | - A Marchand
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France
| | - J Mazereeuw-Hautier
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), Hospital Larrey, University Hospital Center of Toulouse, 31059 Toulouse Cedex 9, France
| | - O Boccara
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), France Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France
| | - L Martin
- Department of Dermatology, University Hospital Center of Angers, 49000 Angers, France
| | - C Chiaverini
- Department of Dermatology, University Hospital Center of Nice, 06000 Nice, France
| | - N Beneton
- Department of Dermatology, Hospital Center of le Mans, 72000 Le Mans, France
| | - P Vabres
- Department of Dermatology, University Hospital Center of Dijon, Reference center for genodermatoses and rare skin diseases (MAGEC), 21000 Dijon, France
| | - X Balguerie
- Department of Dermatology, University Hospital Center of Rouen, 76000 Rouen, France
| | - P Plantin
- Department of Dermatology, Hospital Center of Quimper, 29000 Quimper, France
| | - D Bessis
- Department of Dermatology, University Hospital Center of Montpellier, 34000 Montpellier, France
| | - S Barbarot
- Department of Dermatology, University Hospital Center of Nantes, 44000 Nantes, France
| | - A Dadban
- Department of Dermatology, University Hospital Center of Amiens, 80000 Amiens, France
| | - C Droitcourt
- Department of Dermatology, University Hospital Center of Rennes, 35000 Rennes, France
| | - M Samimi
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France
| | - B Morel
- CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Department of Pediatric Radiology, 37000 Tours, France
| | - A Caille
- CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - A Maruani
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - S Leducq
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France.
| | | |
Collapse
|
10
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, Mcpherson T, Akinde M, Maruani A, Epishev R, Vidaurri De La Cruz H, Luna P, Amy De La Breteque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, Van Den Reek J, Sonkoly E, Kupfer-Bessaguet I, Leducq S, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov. Annales de Dermatologie et de Vénéréologie - FMC 2022. [PMCID: PMC9748132 DOI: 10.1016/j.fander.2022.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
11
|
Marchand A, Caille A, Gissot V, Giraudeau B, Lengelle C, Bourgoin H, Largeau B, Leducq S, Maruani A. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial. Trials 2022; 23:557. [PMID: 35804404 PMCID: PMC9270761 DOI: 10.1186/s13063-022-06365-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 04/28/2022] [Indexed: 11/24/2022] Open
Abstract
Background Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be responsible for a heavy burden, inducing pain, aesthetic prejudice, or oozing, bleeding, infections. The natural history of LMLMs is progressive worsening punctuated by acute flares. Therapeutic options include surgery, laser excision, and radiofrequency ablation but all are potentially detrimental and expose to local relapse. Therefore, the management frequently relies on a “watchful waiting” approach. In complicated LMLMs, treatment with oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is often used. Topical applications of sirolimus on the buccal mucosae have been reported in other oral diseases with good tolerance and none to slight detectable blood sirolimus concentrations. We aim to evaluate the efficacy and safety of a 1 mg/mL sirolimus solution applied once daily on LMLM of any stage in children and adults after 4, 8, 12, 16, 20, and 24 weeks of treatment compared to usual care (no treatment). Methods This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus usual care (no treatment), the control condition. Participants begin with an observational period and later switch to the intervention at a randomized time (week 0, 4, 8, or 12). Visits occur every 4 weeks, either in the study center or by teleconsulting. The primary outcome will be the evaluation of global severity of the LMLM on monthly standardized photographs by 3 independent blinded experts using the physical global assessment (PGA) 0 to 5 scale. Secondary outcomes will include lesion size measurement and quality of life assessment, investigator, and patient-assessed global disease and specific symptoms (oozing, bleeding, sialorrhea, eating impairment, taste modification, aesthetic impairment, pain, and global discomfort) assessment. A biological monitoring will be performed including residual blood sirolimus concentration and usual laboratory parameters. Discussion Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated. Trial registration ClinicalTrials.gov NCT04128722. Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours – CHRU Tours): DR190041-TOPGUN French regulatory authorities: ID RCB: 2019-001530-33 Supplementary Information The online version contains supplementary material available at 10.1186/s13063-022-06365-y.
Collapse
Affiliation(s)
- A Marchand
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France.
| | - A Caille
- Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.,INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France
| | - V Gissot
- Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.,INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France
| | - B Giraudeau
- Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.,INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France
| | - C Lengelle
- Pharmacovigilance Regional Centre (CRPV), CHRU Tours, 37000, Tours, France
| | - H Bourgoin
- Department of Pharmacy, University Hospital Center of Tours, 37000, Tours, France
| | - B Largeau
- Department of Pharmacy, University Hospital Center of Tours, 37000, Tours, France
| | - S Leducq
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France.,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France.,INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France
| | - A Maruani
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC), CHRU Tours, Avenue de la République, 37044, Tours, Cedex 9, France. .,Clinical Investigation Center, INSERM 1415, CHRU Tours, 37000, Tours, France. .,INSERM U1246 -SPHERE « MethodS in Patients-centered outcomes and HEalth REsearch », University of Nantes, University of Tours, 37000, Tours, France.
| |
Collapse
|
12
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, McPherson T, Akinde M, Maruani A, Epishev R, Vidaurri de la Cruz H, Luna P, Amy de la Bretêque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, van den Reek J, Sonkoly E, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). J Eur Acad Dermatol Venereol 2022; 36:2076-2086. [PMID: 35748102 PMCID: PMC9349726 DOI: 10.1111/jdv.18361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 06/10/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
Collapse
Affiliation(s)
- J. Zitouni
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | - A.‐C. Bursztejn
- Department of DermatologyHôpitaux de Brabois, Centre Hospitalier Universitaire de NancyVandœuvre‐lès‐NancyFrance
| | - A. Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMEDUniversity of PadovaPadovaItaly
| | - A. Beauchet
- Department of Public HealthHôpital Ambroise ParéBoulogne‐BillancourtFrance
| | - V. Di Lernia
- Dermatology UnitArcispedale S. Maria Nuova, Azienda USL‐IRCCS di Reggio EmiliaReggio EmiliaItaly
| | - A. Lesiak
- Department of Dermatology, Peadiatric Dermatology and OncologyMedical Univeristy of LodzLodzPoland
| | - J. Thomas
- J. T. Skin Care CentreChennaiTamil NaduIndia
| | - Z. Topkarci
- Department of DermatologyDr. Sadi Konuk Training and Research HospitalIstanbulTurkey
| | - N. Murashkin
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - P. Brzezinski
- Department of DermatologyVoivodship Specialist Hospital in SlupskUstkaPoland
| | - T. Torres
- Department of DermatologyCentro Hospitalar Universitário do PortoPortoPortugal
| | - A. Chiriac
- Department of Dermatology, Nicolina Medical CenterP. Poni Institute of Macromolecular Chemistry, Romanian AcademyIașiRomania
| | - C. Luca
- Infectious Disease Department, “Sf. Parascheva” Clinical Hospital“Gr. T. Popa” University of MedicineIasiRomania
| | - T. McPherson
- Department of DermatologyOxford University Hospitals NHS TrustOxfordUK
| | - M. Akinde
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - A. Maruani
- Unit of Pediatric Dermatology, Department of DermatologyUniversity of Tours and Nantes, INSERM 1246 SPHERE ‐ CHRU ToursToursFrance
| | - R. Epishev
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - H. Vidaurri de la Cruz
- Servicio de Dermatología PediátricaHospital General de México Dr. Eduardo Liceaga, Secretaría de SaludCiudad de MéxicoMexico
| | - P.C. Luna
- Department of DermatologyHospital AlemánCiudad Autónoma de Buenos AiresArgentina
| | | | - A. Lasek
- Department of Dermatology, Hôpital Saint Vincent de PaulUniversité Catholique de LilleLilleFrance
| | - E. Bourrat
- Department of DermatologyHôpital Robert Debré, AP‐HPParisFrance
| | - M. Bachelerie
- Department of DermatologyCentre Hospitalier UniversitaireClermont‐FerrandFrance
| | - S. Mallet
- Department of Dermatology, Hôpital de la TimoneAssistance‐publique‐Hôpitaux de MarseilleMarseilleFrance
| | - M. Steff
- Department of DermatologyCentre Hospitalier Intercommunal Robert BallangerAulnay‐sous‐BoisFrance
| | - A. Bellissen
- Department of DermatologyCentre Hospitalier Edmond GarcinAubagneFrance
| | - I. Neri
- Department of DermatologyIRCSS Azienda Ospedaliero Universitaria di BolognaBolognaItaly
| | - E. Zafiriou
- Department of Dermatology, Faculty of Medicine, School of Health SciencesUniversity of ThessalyLarissaGreece
| | | | - E. Sonkoly
- Dermatology and Venereology Division, Department of Medicine SolnaKarolinska InstitutetStockholmSweden,Center for Molecular Medicine (CMM)Karolinska InstitutetStockholmSweden,Dermatology, Department of Medical SciencesUppsala UniversityUppsalaSweden
| | - S.K. Mahil
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C.H. Smith
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C. Flohr
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - H. Bachelez
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,Laboratory of Genetic Skin Diseases, INSERM U1163, Imagine InstituteUniversité de ParisParisFrance
| | - E. Mahé
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | | |
Collapse
|
13
|
Allemang-Trivalle A, Leducq S, Maruani A, Giraudeau B. Designs des études thérapeutiques dans les anomalies vasculaires rares à expression cutanée. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
14
|
Labonnelie A, Soupre V, Maruani A, Cisternino S, Hadj‐Rabia S, Boccara O. Management of sirolimus treatment for tumors associated with Kasabach‐Merritt phenomenon. J Eur Acad Dermatol Venereol 2022; 36:e586-e588. [DOI: 10.1111/jdv.18077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 03/04/2022] [Indexed: 11/30/2022]
Affiliation(s)
- A. Labonnelie
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| | - V. Soupre
- Department of pediatric maxillo‐facial and plastic surgery University Hospital of Necker‐Enfants Malades, APHP5 Paris France
| | - A. Maruani
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) Universities of Nantes and Tours, INSERM 1246‐SPHERE; CHRU Tours Tours France
| | - S. Cisternino
- Department of pharmacy APHP5, University Hospital Necker – Enfants Malades University of Paris, Faculté de Pharmacie, Optimisation Thérapeutique en Neuropsychopharmacologie F‐75006 Paris France
- INSERM UMR‐S 1144 Paris France
| | - S. Hadj‐Rabia
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| | - O. Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) University of Paris, Paris‐centre, Institut Imagine, University Hospital Necker‐Enfants Malades, APHP5 Paris France
| |
Collapse
|
15
|
Lechevalier D, Sigg N, Humeau H, Vermersch C, Leducq S, Maruani A, Martin L. Healthcare transition from childhood to adulthood in pseudoxanthoma elasticum: Patient experience and recommendations for health practitioners. Ann Dermatol Venereol 2022; 149:191-194. [DOI: 10.1016/j.annder.2022.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 11/04/2021] [Accepted: 02/01/2022] [Indexed: 12/01/2022]
|
16
|
Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, Morice-Picard F, Petit F, Willems M, Bessis D, Jacquemont ML, Maruani A, Chiaverini C, Mirault T, Clayton-Smith J, Carpentier M, Fleck C, Maurer A, Yousfi M, Parker VER, Semple RK, Bardou M, Faivre L. Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Genet Med 2021; 23:2433-2442. [PMID: 34385668 PMCID: PMC8631579 DOI: 10.1038/s41436-021-01290-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 07/13/2021] [Accepted: 07/13/2021] [Indexed: 11/08/2022] Open
Abstract
PURPOSE PIK3CA pathogenic variants in the PIK3CA-related overgrowth spectrum (PROS) activate phosphoinositide 3-kinase signaling, providing a rationale for targeted therapy, but no drug has proven efficacy and safety in this population. Our aim was to establish the six-month tolerability and efficacy of low-dose taselisib, a selective class I PI3K inhibitor, in PROS patients. METHODS Patients over 16 years with PROS and PIK3CA pathogenic variants were included in a phase IB/IIA multicenter, open-label single-arm trial (six patients at 1 mg/day of taselisib, then 24 at 2 mg/day). The primary outcome was the occurrence of dose limiting toxicity (DLT). Efficacy outcomes were the relative changes after treatment of (1) tissue volume at affected and unaffected sites, both clinically and on imaging; (2) cutaneous vascular outcomes when relevant; (3) biologic parameters; (4) quality of life; and (5) patient-reported outcomes. RESULTS Among 19 enrolled patients, 2 experienced a DLT (enteritis and pachymeningitis) leading to early trial termination (17 treated, 10 completed the study). No serious adverse reaction occurred in the 1 mg cohort (n = 6). No significant reduction in affected tissue volume was observed (mean -4.2%; p = 0.81; SD 14.01). Thirteen (76.4%) participants reported clinical improvement (pain reduction, chronic bleeding resolution, functional improvement). CONCLUSION Despite functional improvement, the safety profile of low-dose taselisib precludes its long-term use.
Collapse
Affiliation(s)
- M Luu
- Centre d'Investigation Clinique-module plurithématique, CHU, Dijon, France.
- INSERM CIC1432, UBFC, Dijon, France.
| | - P Vabres
- Centre référence MAGEC, Dijon, France
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU, Dijon, France
| | - H Devilliers
- INSERM CIC1432, UBFC, Dijon, France
- Centre d'Investigation Clinique-module épidémiologie clinique, CHU, Dijon, France
| | - R Loffroy
- Radiologie Interventionnelle, CHU, Dijon, France
| | - A Phan
- Dermatologie Pédiatrique, HFME, Lyon, France
| | - L Martin
- Centre référence MAGEC, CHU, Angers, France
| | | | - F Petit
- Centre de référence Anomalies du Développement et Syndromes Malformatifs, CHU, Lille, France
| | - M Willems
- Centre de référence Anomalies du Développement et Syndromes Malformatifs, Montpellier, France
| | - D Bessis
- Service de Dermatologie, CHU, Montpellier, France
| | - M L Jacquemont
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU La Réunion, Saint-Pierre, France
| | - A Maruani
- Centre référence MAGEC, CHU, Tours, France
| | | | - T Mirault
- Centre de référence maladies vasculaires rares, Hôpital européen Georges-Pompidou, AP-HP, Paris, France
- INSERM U970 PARCC, Université de Paris, Paris, France
| | - J Clayton-Smith
- Clinical Genetics and Manchester Centre for Genomic Medicine, NHS and Manchester University, Manchester, UK
| | - M Carpentier
- Délégation à la Recherche Clinique et de l'Innovation, CHU, Dijon, France
| | - C Fleck
- Délégation à la Recherche Clinique et de l'Innovation, CHU, Dijon, France
| | - A Maurer
- Centre d'Investigation Clinique-module plurithématique, CHU, Dijon, France
- INSERM CIC1432, UBFC, Dijon, France
| | - M Yousfi
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU, Dijon, France
| | | | - R K Semple
- Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
| | - M Bardou
- Centre d'Investigation Clinique-module plurithématique, CHU, Dijon, France
- INSERM CIC1432, UBFC, Dijon, France
| | - L Faivre
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU, Dijon, France
- INSERM UMR1231 GAD, Génétique des Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon, France
| |
Collapse
|
17
|
Largeau B, Agier MS, Beau-Salinas F, Pariente A, Maruani A, Vial T, Jonville-Béra AP. Specific features of amoxicillin-associated Drug Reaction with Eosinophilia and Systemic Symptoms syndrome: a nationwide study. J Eur Acad Dermatol Venereol 2021; 35:2415-2420. [PMID: 34459032 DOI: 10.1111/jdv.17631] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 08/11/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND Growing evidence indicates that amoxicillin induces herpesvirus replication in vitro. As these play a central pathophysiological role in Drug Reaction with Eosinophilia and Systemic Symptoms syndrome (DRESS), amoxicillin could present with specific DRESS features. OBJECTIVE To characterize the onset patterns of amoxicillin-associated DRESS. METHODS All cases of DRESS (Kardaun score ≥4) involving amoxicillin and reported in the French Pharmacovigilance Database between January 1, 2004 and November 30, 2019 were included. Onset circumstances for these cases were categorized considering the onset delay from amoxicillin initiation, and the presence of concomitant medications with a compatible time to onset. RESULTS A total of 146 probable cases or definite cases of DRESS were included. Three onset circumstances were identified: (i) 'amoxicillin clear culprit' where amoxicillin was the sole suspect drug or when concomitant drugs of compatible time to onset were not reported to cause DRESS (n = 62); (ii) 'amoxicillin possible culprit' in the presence of other potentially culprit drugs in addition to amoxicillin (n = 44) and (iii) 'flare' where amoxicillin, used after DRESS onset, induced flare-up reactions (n = 40). The median time to onset was 5 days (IQR 2-11) in 'clear culprit', and 18 days (IQR 7-26) in 'possible culprit' cases. In 'flare' cases, the median latency between amoxicillin initiation and flare-up reactions was 3 days (IQR 2-5). CONCLUSIONS Amoxicillin can induce DRESS with a specific early onset and exacerbate DRESS from another drug.
Collapse
Affiliation(s)
- B Largeau
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France
| | - M-S Agier
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.,Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours, France
| | - F Beau-Salinas
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France
| | - A Pariente
- CHU Bordeaux, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, Bordeaux, France.,Université de Bordeaux, INSERM, Bordeaux Population Health Research (BPH) Research Center - UMR 1219, Team Pharmacoepidemiology, Bordeaux, France
| | - A Maruani
- Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours, France.,Service de Dermatologie, CHRU de Tours, Tours, France
| | - T Vial
- Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, Centre Régional de Pharmacovigilance, Lyon, France
| | - A-P Jonville-Béra
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.,Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours, France
| |
Collapse
|
18
|
Sorlin A, Carmignac V, Amiel J, Boccara O, Fraitag S, Maruani A, Theiler M, Weibel L, Duffourd Y, Philippe C, Thauvin-Robinet C, Faivre L, Rivière JB, Vabres P, Kuentz P. Expanding the clinical spectrum of mosaic BRAF skin phenotypes. J Eur Acad Dermatol Venereol 2021; 35:e690-e693. [PMID: 34051131 DOI: 10.1111/jdv.17413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 05/19/2021] [Indexed: 11/28/2022]
Affiliation(s)
- A Sorlin
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - V Carmignac
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - J Amiel
- Service de Génétique Médicale, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - O Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - S Fraitag
- Service d'Anatomie et de Cytologie Pathologiques, APHP, Hôpital Necker-Enfants Malades, Paris, France
| | - A Maruani
- Service de Dermatologie, Centre de Référence des Maladies Rares - MAGEC, Centre Hospitalier Universitaire de Tours, Université de Tours, SPHERE-INSERM 1246, Tours, France
| | - M Theiler
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - L Weibel
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - Y Duffourd
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - C Philippe
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - L Faivre
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - J-B Rivière
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - P Vabres
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Service de Dermatologie, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - P Kuentz
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France
| |
Collapse
|
19
|
Hacard F, Giraudeau B, d'Acremont G, Jegou MH, Jonville-Bera AP, Munck S, Pham BN, Mavoungou S, Cornillier H, Guillot B, Beylot-Barry M, Chosidow O, Maruani A. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol 2021; 185:658-660. [PMID: 33913519 PMCID: PMC8457139 DOI: 10.1111/bjd.20415] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 04/19/2021] [Accepted: 04/23/2021] [Indexed: 11/30/2022]
Affiliation(s)
- F Hacard
- Department of Allergology and Clinical Immunology, University Hospital of Lyon, 69495, Lyon, France
| | - B Giraudeau
- Universities of Tours and Nantes, 37000, Tours, France
| | | | - M-H Jegou
- Dermatology Office, 33290, Blanquefort, France
| | - A-P Jonville-Bera
- Universities of Tours and Nantes, 37000, Tours, France.,University Hospital of Tours, 37000, Tours, France
| | - S Munck
- Department of Teaching and Research in General Practice, University Nice Sophia Antipolis, 06000, Nice, France
| | - B-N Pham
- University Hospital of Reims, 51000, Reims, France
| | - S Mavoungou
- Centre of Evidence of the French Society of Dermatology, 75009, Paris, France
| | - H Cornillier
- University Hospital Centre of Tours, 37044, Tours CEDEX 9, France
| | - B Guillot
- University of Montpellier, 34000, Montpellier, France
| | - M Beylot-Barry
- University Hospital of Bordeaux, 33000, Bordeaux, France
| | - O Chosidow
- Centre of Evidence of the French Society of Dermatology, 75009, Paris, France.,AP-HP, Henri Mondor Hospital, Paris-Est University, 94010, Créteil, France
| | - A Maruani
- Universities of Tours and Nantes, 37000, Tours, France.,University Hospital Centre of Tours, 37044, Tours CEDEX 9, France
| |
Collapse
|
20
|
Andina D, Belloni‐Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El‐Hachem M, Fertitta L, Gysel D, Hernández‐Martín A, Hubiche T, Luca C, Martos‐Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A. Skin manifestations of COVID-19 in children: Part 2. Clin Exp Dermatol 2021; 46:451-461. [PMID: 33166429 PMCID: PMC9275399 DOI: 10.1111/ced.14482] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 08/13/2020] [Indexed: 01/09/2023]
Abstract
The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.
Collapse
Affiliation(s)
- D. Andina
- Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid
Spain
| | - A. Belloni‐Fortina
- Pediatric Dermatology Unit Department of Medicine DIMED University of Padua
Padua Italy
| | - C. Bodemer
- Department of Dermatology Hospital Necker Enfants MaladesParis Centre
University Paris France
| | - E. Bonifazi
- Dermatologia Pediatrica Association Bari Italy
| | | | - I. Colmenero
- Department of Pathology Hospital Infantil Universitario Niño Jesús Madrid
Spain
| | - A. Diociaiuti
- Dermatology Unit Bambino Gesù Children’s HospitalIRCCS Rome
Italy
| | - M. El‐Hachem
- Dermatology Unit Bambino Gesù Children’s HospitalIRCCS Rome
Italy
| | - L. Fertitta
- Department of Dermatology Hospital Necker Enfants MaladesParis Centre
University Paris France
| | - D. Gysel
- Department of Pediatrics O. L. Vrouw Hospital Aalst Belgium
| | - A. Hernández‐Martín
- Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid
Spain
| | - T. Hubiche
- Department of Dermatology Université Côte d'Azur Nice France
| | - C. Luca
- Nicolina Medical Center Iasi Romania
| | - L. Martos‐Cabrera
- Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid
Spain
| | - A. Maruani
- Department of Dermatology Unit of Pediatric Dermatology University of
ToursSPHERE‐INSERM1246, CHRU Tours Tours France
| | - F. Mazzotta
- Dermatologia Pediatrica Association Bari Italy
| | - A. D. Akkaya
- Department of Dermatology Ulus Liv Hospital Istanbul Turkey
| | - M. Casals
- Department of Dermatology Hospital Universitari de Sabadell Barcelona
Spain
| | - J. Ferrando
- Department of Dermatology Hospital Clìnic Barcelona Spain
| | - R. Grimalt
- Faculty of Medicine and Health Sciences Universitat Internacional de
Catalunya Barcelona Spain
| | - I. Grozdev
- Department of Dermatology Children's University Hospital Queen Fabiola
Brussels Belgium
| | - V. Kinsler
- Department of Paediatric Dermatology Great Ormond Street Hospital for
Children NHS Foundation Trust London UK
| | - M. A. Morren
- Pediatric Dermatology Unit Department of Pediatrics and Dermato‐Venereology
University Hospital Lausanne and University of Lausanne Lausanne
Switzerland
| | - M. Munisami
- Department of Dermatology and Sexually Transmitted Diseases Jawaharlal
Institute of Postgraduate Medical Education and Research (JIPMER) Puducherry
India
| | - A. Nanda
- As'ad Al‐Hamad Dermatology Center Kuwait City Kuwait
| | - M. P. Novoa
- Department of Dermatology Hospital San Jose Bogota Colombia
| | - H. Ott
- Division of Pediatric Dermatology Children’s Hospital Auf der Bult Hannover
Germany
| | - S. Pasmans
- Erasmus MC University Medical Center RotterdamSophia Children's Hospital
Rotterdam The Netherlands
| | - C. Salavastru
- Department of Paediatric Dermatology Colentina Clinical HospitalCarol
Davila University of Medicine and Pharmacy Bucharest Romania
| | - V. Zawar
- Department of Dermatology Dr Vasantrao Pawar Medical College Nashik
India
| | - A. Torrelo
- Correspondence: Dr Antonio Torrelo, Department of Dermatology, Hospital
Niño Jesús, Menendez Pelayo 65, Madrid 28034, Spain E‐mail:
| | | |
Collapse
|
21
|
Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol 2021; 148:106-111. [PMID: 33637347 PMCID: PMC7901834 DOI: 10.1016/j.annder.2021.01.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/04/2020] [Accepted: 01/18/2021] [Indexed: 12/19/2022]
Abstract
Background Children with psoriasis may have been directly impacted by the COVID-19 pandemic and their illness may also have affected their ability to follow preventive measures. Objective To investigate the impact of the COVID-19 pandemic on children with psoriasis. Methods A survey of children (< 18 years) with psoriasis, conducted from June 10 to June 29, 2020. Results In total, 92 children were included: 71.7% had psoriasis lesions at the time of home lockdown while 45.2% were receiving systemic treatments, and two contracted COVID-19. During lockdown, psoriasis worsened in 47.3% of the children and 18.8% stopped their systemic treatments, mainly for reasons linked to the pandemic. A total of 41.3% had a consultation for psoriasis during lockdown (71.1% by teleconsultation): 39.5% due to worsening of their psoriasis and 21.1% for pandemic-related issues. Among patients not having a consultation during lockdown, 27.5% had a cancellation by the doctor and 9.3% had concerns over going to see the doctor. Finally, 22.8% of patients reported finding it difficult to respect hygiene measures because of their psoriasis, e.g., application of alcohol-based hand sanitizers (47.6%), handwashing routines (42.9%), and wearing a mask (28.6%). Conclusions This study demonstrates the major clinical impact of the COVID-19 pandemic on children with psoriasis. Teleconsultations played a key role in patient management as regards patient monitoring, provision of information, and renewal of treatments. It is vital that we learn from these data to improve and adapt the monitoring of chronic dermatoses in both children and adults in the event of a future health crisis.
Collapse
Affiliation(s)
- Q Beytout
- Service de dermatologie, hôpital Victor-Dupouy, 69, rue du Lieutenant Colonel-Prudhon, 95107 Argenteuil cedex, France
| | - J Pepiot
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - A Maruani
- Inserm 1246-SPHERE, unité de dermatologie pédiatrique, service de dermatologie, CHRU Tours, université de Tours, 2, boulevard Tonnellé, 37000 Tours, France
| | - D Devulder
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - R Aubert
- Association France Psoriasis, 53, rue Compans, 75019 Paris, France
| | - M Beylot-Barry
- Inserm u 1053. UMR BaRiton, service de dermatologie, hôpital Saint-André, CHU de Bordeaux, université de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - J-M Amici
- Dermatologie, Cabinet Libéral, 36, avenue René-Cassagne, 33150 Cenon, France
| | - D Jullien
- Service de dermatologie, hôpital Edouard-Herriot, hôpitaux civils de Lyon, 5, place d'Arsonval, 69003 Lyon, France
| | - E Mahé
- Service de dermatologie, hôpital Victor-Dupouy, 69, rue du Lieutenant Colonel-Prudhon, 95107 Argenteuil cedex, France.
| |
Collapse
|
22
|
Hubiche T, Phan A, Leducq S, Rapp J, Fertitta L, Aubert H, Barbarot S, Chiaverini C, Giraudeau B, Lasek A, Mallet S, Labarelle A, Piram M, McCuaig C, Martin L, Monitor L, Nicol I, Bissuel M, Bellissen A, Jullien D, Lesort C, Vabres P, Maruani A. Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters. Ann Dermatol Venereol 2021; 148:94-100. [PMID: 33551211 PMCID: PMC7831537 DOI: 10.1016/j.annder.2020.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 10/15/2020] [Accepted: 11/26/2020] [Indexed: 12/20/2022]
Abstract
Background A marked increase in frequency of acute acral eruptions (AAE) was observed in children during the COVID-19 pandemic in the spring period. Objectives In this observational multicenter study, based on children with AAE, we aimed to assess the proportion of household members possibly infected by SARS-CoV-2. Methods We collected data from all children observed with AAE, prospectively from April 7, 2020 to June 22, 2020, and retrospectively since February 28, 2020. The primary outcome was the household infection rate, defined as the proportion of family clusters having at least one member with COVID-19 infection other than the child with AAE (“index child”). The definition of a case was based on characteristic clinical signs and a positive PCR or serology. Results The study included 103 children in 10 French departments and in Quebec. The median age was 13 years and the interquartile range [8–15], with a female-to-male ratio of 1/1.15. In children with AAE, all PCR tests were negative (n = 18), and serology was positive in 2/14 (14.3%) cases. We found no significant anomalies in the lab results. A total of 66 of the 103 families (64.1%) of included children had at least one other infected member apart from the index child. The total number of household members was 292, of whom 119 (40.8%) were considered possibly infected by SARS-CoV-2. No index children or households exhibited severe COVID-19. Discussion Among the 103 households included, 64.1% had at least one infected member. Neither children with AAE nor their households showed severe COVID-19.
Collapse
Affiliation(s)
- T Hubiche
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - A Phan
- Lyon University Hospital, Department of Pediatric Dermatology, Hospices Civils de Lyon, 69500 Bron, France
| | - S Leducq
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France
| | - J Rapp
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - L Fertitta
- AP-HP (Paris Hospitals), Paris-Necker Hospital, Department of Dermatology, 75015 Paris, France
| | - H Aubert
- Nantes University Hospital, Department of Dermatology, 44000 Nantes, France
| | - S Barbarot
- Nantes University Hospital, Department of Dermatology, 44000 Nantes, France
| | - C Chiaverini
- Nice University Hospital, Department of Dermatology, 06000 Nice, France
| | - B Giraudeau
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France
| | - A Lasek
- Saint Vincent de Paul Hospital, Université catholique de Lille, 59000 Lille, France
| | - S Mallet
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - A Labarelle
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - M Piram
- Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada
| | - C McCuaig
- Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada
| | - L Martin
- Angers Hospital University, Department of Dermatology, 49000 Angers, France
| | - L Monitor
- Nancy University Hospital, Department of Dermatology, 54511 Vandœuvre-lès-Nancy, France
| | - I Nicol
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - M Bissuel
- Casamance Private Hospital, Department of Pediatrics, 13400 Aubagnes, France
| | - A Bellissen
- Marseille University Hospital, Department of Dermatology, 13000 Marseille, France
| | - D Jullien
- Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France
| | - C Lesort
- Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France
| | - P Vabres
- Dijon University Hospital, Department of Dermatology, 21000 Dijon, France
| | - A Maruani
- Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France.
| | | |
Collapse
|
23
|
Hubiche T, Phan A, Leducq S, Rapp J, Fertitta L, Aubert H, Barbarot S, Chiaverini C, Giraudeau B, Labarelle A, Mc Craig C, Martin L, Monitor L, Nicol I, Piram M, Bissuel M, Bellissen A, Lasek A, Mallet S, Vabres P, Maruani A. Acrosyndromes aigus pédiatriques au cours de l’épidémie de COVID-19 : étude des caractéristiques de la cellule familiale. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Edee A, Maruani A, Taieb C, Bodemer C, Gene R. Émergence des postes paramédicaux de coordination au sein des centres de référence maladies rares : enjeux et défis. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E. Impact de l’épidémie de Covid-19 sur le psoriasis de l’enfant en France. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Morel B, Leducq S, Samimi M, Caille A, Maruani A. Qualité de vie chez les enfants ayant une malformation capillaire de membre inférieur : données dynamiques sur 5 ans (cohorte nationale multicentrique CONAPE). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Bedouelle E, Ben Said B, Tetart F, Milpied B, Welfringer A, Maruani A, Catteau B, Dezoteux F, Staumont-Sallé D, Mazareeuw-Hautier J, Abasq-Thomas C, Chiaverini C, Mahé E, Delaunay J, Mallet S, Sterling B, Puzenat E, Raynal M, Collet E, Bernier C. Drug reaction with eosinophilia and systemic symptoms (DRESS) : série de 53 cas pédiatriques français. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Sanchez A, Mahé E, Miquel J, Abasq C, Phan A, Mazereeuw-Hautier J, Lemille J, Maruani A, Bonniaud B, Plantin P, Mallet S, Martin H, Hubiche T, Chiaverini C, Lacour JP. Intertrigo péri-alaire de l’enfant et de l’adolescent : étude descriptive prospective multicentrique d’une nouvelle entité clinique (Étude TRIGONASO). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Casassa E, Bergeron A, Maruani A, Labreze C, Barbarot S, Aubert H, Malloizel-Delaunay J, Shourick J, Croiset A, Dreyfus I, Mazereeuw-Hautier J. Factors influencing quality of life in children with low-flow vascular malformations: a qualitative study using focus groups. J Eur Acad Dermatol Venereol 2020; 35:755-761. [PMID: 33211344 DOI: 10.1111/jdv.17037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Revised: 09/12/2020] [Accepted: 10/27/2020] [Indexed: 01/19/2023]
Abstract
BACKGROUND Very few studies have evaluated the quality of life (QoL) of children suffering from low-flow vascular malformations. This is the first study investigating the influencing factors. OBJECTIVES To identify the factors influencing QoL in children with low-flow vascular malformations. METHODS We conducted a qualitative study employing focus group interviews (Clinical Trials Number: NCT03440827). The study was a prospective, interventional, non-comparative, multicentre study performed in four expert centres for vascular anomalies. Qualitative data about personal experiences, feelings, difficulties, needs and various factors influencing behaviours were collected. Theme-based content analysis (manual and specialist textural software guided) were used to analyse the verbatim transcripts of all focus group sessions. Manual qualitative discourse analysis was performed to identify the different themes and categories. Informatics' analyses were subsequently performed for each individual category. RESULTS Ten focus groups (26 individuals including 10 children aged 11 to 15 years) were conducted until saturation. Influencing factors were related to 4 categories: medical care, self-image, social impact on daily activities and challenging social relationships. These factors were responsible for intrafamily upheavals and may lead to future identity-building problems. CONCLUSIONS This study provides an essential framework from which physicians can develop strategies to improve patient care and quality of life. These data may also be useful to develop specific age-sensitive QoL questionnaires.
Collapse
Affiliation(s)
- E Casassa
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Toulouse, Paul Sabatier University, Toulouse, France
| | - A Bergeron
- Psycholopathology Department, Centre d'Etudes et de Recherches en Psychopathologie et psychologie de la Santé, Toulouse II Jean Jaurès University, Toulouse, France
| | - A Maruani
- Dermatology Department, CHU Tours, Tours, France
| | - C Labreze
- Reference Centre for Rare Skin Diseases, Dermatology Department, U-1035 Inserm, University of Bordeaux, Bordeaux, France
| | - S Barbarot
- Dermatology Department, CHU Nantes, Nantes, France
| | - H Aubert
- Dermatology Department, CHU Nantes, Nantes, France
| | | | - J Shourick
- Epidémiologie, Pôle santé publique et médecine sociale, Faculté de médecine de Purpan, CHU Toulouse, Toulouse, France
| | - A Croiset
- Dermatology Department, CHU Tours, Tours, France
| | - I Dreyfus
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Toulouse, Paul Sabatier University, Toulouse, France
| | - J Mazereeuw-Hautier
- Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Toulouse, Paul Sabatier University, Toulouse, France
| |
Collapse
|
30
|
Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El-Hachem M, Fertitta L, van Gysel D, Hernández-Martín A, Hubiche T, Luca C, Martos-Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A. Skin manifestations of COVID-19 in children: Part 3. Clin Exp Dermatol 2020; 46:462-472. [PMID: 33207021 PMCID: PMC7753282 DOI: 10.1111/ced.14483] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 08/13/2020] [Indexed: 12/13/2022]
Abstract
The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial
recognized symptoms were respiratory, sometimes culminating in severe respiratory distress
requiring ventilation, and causing death in a percentage of those infected. As time has
passed, other symptoms have been recognized. The initial reports of cutaneous
manifestations were from Italian dermatologists, probably because Italy was the first
European country to be heavily affected by the pandemic. The overall clinical
presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in
adults as do the cutaneous manifestations of childhood. In this review, we summarize the
current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough
and critical review of articles published in the literature and from the personal
experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss
one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like
lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme,
urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In this part of
the review, we discuss the histological findings of COVID‐19 manifestations, and the
testing and management of infected children for both COVID‐19 and any other pre‐existing
conditions. Click here for the corresponding questions to this CME article.
Collapse
Affiliation(s)
- D Andina
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Belloni-Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - C Bodemer
- Department of Dermatology, Hospital Necker Enfants Malades, Paris Centre University, Paris, France
| | - E Bonifazi
- Dermatologia Pediatrica Association, Bari, Italy
| | - A Chiriac
- Nicolina Medical Center, Iasi, Romania
| | - I Colmenero
- Department of Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Diociaiuti
- Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - M El-Hachem
- Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - L Fertitta
- Department of Dermatology, Hospital Necker Enfants Malades, Paris Centre University, Paris, France
| | - D van Gysel
- Department of Pediatrics, O. L. Vrouw Hospital, Aalst, Belgium
| | - A Hernández-Martín
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - T Hubiche
- Department of Dermatology, Université Côte d'Azur, Nice, France
| | - C Luca
- Nicolina Medical Center, Iasi, Romania
| | - L Martos-Cabrera
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Maruani
- Department of Dermatology, Unit of Pediatric Dermatology, University of Tours, SPHERE-INSERM1246, CHRU Tours, Tours, France
| | - F Mazzotta
- Dermatologia Pediatrica Association, Bari, Italy
| | - A D Akkaya
- Department of Dermatology, Ulus Liv Hospital, Istanbul, Turkey
| | - M Casals
- Department of Dermatology, Hospital Universitari de Sabadell, Barcelona, Spain
| | - J Ferrando
- Department of Dermatology, Hospital Clìnic, Barcelona, Spain
| | - R Grimalt
- Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
| | - I Grozdev
- Department of Dermatology, Children's University Hospital Queen Fabiola, Brussels, Belgium
| | - V Kinsler
- Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK
| | - M A Morren
- Pediatric Dermatology Unit, Department of Pediatrics and Dermato-Venereology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland
| | - M Munisami
- Department of Dermatology and Sexually Transmitted Diseases, Jawaharlal Institute Of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
| | - A Nanda
- As'ad Al-Hamad Dermatology Center, Kuwait City, Kuwait
| | - M P Novoa
- Department of Dermatology, Hospital San Jose, Bogota, Colombia
| | - H Ott
- Division of Pediatric Dermatology, Children's Hospital Auf der Bult, Hannover, Germany
| | - S Pasmans
- Erasmus MC University Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands
| | - C Salavastru
- Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - V Zawar
- Department of Dermatology, Dr Vasantrao Pawar Medical College, Nashik, India
| | - A Torrelo
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | | |
Collapse
|
31
|
Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El-Hachem M, Fertitta L, van Gysel D, Hernández-Martín A, Hubiche T, Luca C, Martos-Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A. Skin manifestations of COVID-19 in children: Part 1. Clin Exp Dermatol 2020; 46:444-450. [PMID: 33180982 PMCID: PMC9275402 DOI: 10.1111/ced.14481] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 08/13/2020] [Indexed: 01/08/2023]
Abstract
The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial
recognized symptoms were respiratory, sometimes culminating in severe respiratory distress
requiring ventilation, and causing death in a percentage of those infected. As time has
passed, other symptoms have been recognized. The initial reports of cutaneous
manifestations were from Italian dermatologists, probably because Italy was the first
European country to be heavily affected by the pandemic. The overall clinical
presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in
adults as do the cutaneous manifestations of childhood. In this review, we summarize the
current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough
and critical review of articles published in the literature and from the personal
experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss
one of the first and most widespread cutaneous manifestation of COVID‐19, chilblain‐like
lesions. In Part 2, we review other manifestations, including erythema multiforme,
urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome, while in Part 3,
we discuss the histological findings of COVID‐19 manifestations, and the testing and
management of infected children, for both COVID‐19 and any other pre‐existing
conditions. Click here for the corresponding questions to this CME article.
Collapse
Affiliation(s)
- D Andina
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Belloni-Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - C Bodemer
- Department of Dermatology, Hospital Necker Enfants Malades, Paris Centre University, Paris, France
| | - E Bonifazi
- Dermatologia Pediatrica Association, Bari, Italy
| | - A Chiriac
- Nicolina Medical Center, Iasi, Romania
| | - I Colmenero
- Department of Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Diociaiuti
- Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - M El-Hachem
- Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - L Fertitta
- St Parascheva Infectious Diseases Hospital, Iasi, Romania
| | - D van Gysel
- Department of Pediatrics, O. L. Vrouw Hospital, Aalst, Belgium
| | - A Hernández-Martín
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - T Hubiche
- Department of Dermatology, Université Côte d'Azur, Nice, France
| | - C Luca
- Nicolina Medical Center, Iasi, Romania
| | - L Martos-Cabrera
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | - A Maruani
- Department of Dermatology, Unit of Pediatric Dermatology, University of Tours, SPHERE-INSERM1246, CHRU Tours, Tours, France
| | - F Mazzotta
- Dermatologia Pediatrica Association, Bari, Italy
| | - A D Akkaya
- Department of Dermatology, Ulus Liv Hospital, Istanbul, Turkey
| | - M Casals
- Department of Dermatology, Hospital Universitari de Sabadell, Barcelona, Spain
| | - J Ferrando
- Department of Dermatology, Hospital Clìnic, Barcelona, Spain
| | - R Grimalt
- Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
| | - I Grozdev
- Department of Dermatology, Children's University Hospital Queen Fabiola, Brussels, Belgium
| | - V Kinsler
- Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK
| | - M A Morren
- Pediatric Dermatology Unit, Department of Pediatrics and Dermato-Venereology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland
| | - M Munisami
- Department of Dermatology and Sexually Transmitted Diseases, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
| | - A Nanda
- As'ad Al-Hamad Dermatology Center, Kuwait City, Kuwait
| | - M P Novoa
- Department of Dermatology, Hospital San Jose, Bogota, Colombia
| | - H Ott
- Division of Pediatric Dermatology, Children's Hospital Auf der Bult, Hannover, Germany
| | - S Pasmans
- Erasmus MC University Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands
| | - C Salavastru
- Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - V Zawar
- Department of Dermatology, Dr Vasantrao Pawar Medical College, Nashik, India
| | - A Torrelo
- Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
| | | |
Collapse
|
32
|
Leducq S, Maruani A, Samimi M, Tavernier E, Passeron T, Fontas E, Le Cleach L, Caille A, Giraudeau B. Design issues when assessing a topical pharmacological treatment in dermatology. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
33
|
Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw‐Hautier J, Maruani A. Modalities of use of oral propranolol in proliferative infantile haemangiomas: an international survey among practitioners. Br J Dermatol 2020; 183:573-575. [DOI: 10.1111/bjd.19047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- J. Robert
- CHRU Tours, Department of Dermatology Unit of Pediatric Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC) CHRU Tours 37044 Tours CEDEX 9 France
| | - E. Tavernier
- Universities of Tours and Nantes INSERM 1246 – SPHERE 37000 Tours France
- CHRU Tours Clinical Investigation Center – INSERM 1415 37044 Tours CEDEX 9 France
| | - O. Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC) Université Paris Paris‐Centre, Institut Imagine Hôpital Universitaire Necker‐Enfants Malades APHP Paris France
| | - J. Mashiah
- Pediatric Dermatology Unit Dana Children's Hospital Department of Dermatology and Venereology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel
- Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel
| | | | - A. Maruani
- CHRU Tours, Department of Dermatology Unit of Pediatric Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC) CHRU Tours 37044 Tours CEDEX 9 France
- Universities of Tours and Nantes INSERM 1246 – SPHERE 37000 Tours France
| |
Collapse
|
34
|
Chambrelan E, Barbarot S, Bekel L, Poizeau F, Mahé E, Puzenat E, Delaunay J, Mallet S, Bessis D, Maruani A, Miquel J, Raison-Peyron N, Abasq C, Phan A, Du Thanh A, Kupfer I, Bonniaud B, Bouzille G, Dupuy A, Droitcourt C. Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis. Br J Dermatol 2020; 183:376-378. [PMID: 32037515 DOI: 10.1111/bjd.18941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Chambrelan
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France
| | - S Barbarot
- Department of Dermatology, CHU Nantes, F44093, Nantes, France
| | - L Bekel
- Department of Dermatology and Pediatric Dermatology, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris (APHP), F75015, Paris, France
| | - F Poizeau
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - A Dupuy
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes 1, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | | |
Collapse
|
35
|
Ventéjou S, Uetwiller F, Machet MC, de Muret A, Samimi M, Maruani A, Cornillier H. Identification d’une nouvelle mutation de NOD2 chez un nourrisson ayant un syndrome de Blau de révélation précoce. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Poizeau F, Balusson F, Jonville-Béra AP, Scarabin PY, Drici MD, Maruani A, Droitcourt C, Happe A, Nowak E, Oger E, Dupuy A. Risque cardiovasculaire associé à l’alitrétinoïne. Analyse de la population française par la base SNDS-SNIIRAM. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
37
|
Luu M, Vabres P, Devilliers H, Loffroy R, Carpentier M, Maurer A, Yousfi M, Fleck C, Phan A, Martin L, Morice-Picard F, Petit F, Willems M, Bessis D, Jacquemont ML, Maruani A, Chiaverini C, Bardou M, Faivre L. Enseignements de l’essai TOTEM évaluant le tasélisib, inhibiteur de la PI3 K, dans les syndromes hypertrophiques liés à PIK3CA. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
38
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani A, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance de scores d’activité évalués sur photographies dans l’hidradénite suppurée. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Leducq S, Samimi M, Bernier C, Soria A, Amsler E, Staumont-Sallé D, Gabison G, Chosidow O, Bénéton N, Bara C, Grange-Prunier A, Wierzbicka-Hainaut E, Brenaut E, Droitcourt C, Rayson-Peyron N, Bourgoin H, Cornillier H, Machet L, Giraudeau B, Caille A, Maruani A. Efficacité du méthotrexate en adjonction d’un traitement par anti-histaminiques H1 dans le traitement de l’urticaire chronique spontanée sévère réfractaire aux anti-H1 seuls : essai de phase III, randomisé, en double aveugle (NCT01960283). Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Robert J, Tavernier E, Boccara O, Mashiah J, Mazereeuw-Hautier J, Maruani A. Modalités d’utilisation du propranolol dans les hémangiomes infantiles : un questionnaire international auprès des praticiens. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Lévy J, Grotto S, Mignot C, Maruani A, Delahaye-Duriez A, Benzacken B, Keren B, Haye D, Xavier J, Heulin M, Charles E, Verloes A, Dupont C, Pipiras E, Tabet AC. NR4A2 haploinsufficiency is associated with intellectual disability and autism spectrum disorder. Clin Genet 2019; 94:264-268. [PMID: 29770430 DOI: 10.1111/cge.13383] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 05/10/2018] [Accepted: 05/11/2018] [Indexed: 01/15/2023]
Abstract
NR4A2, a member of the nuclear receptor superfamily, is involved in modulation of target gene transcription, regulating several developmental processes such as regulation of cellular homeostasis, neuronal development, inflammation and carcinogenesis. 2q24.1 deletions are extremely rare, and only 1 patient with a de novo deletion encompassing only NR4A2 gene was reported so far. We report 3 additional patients with a de novo deletion encompassing NR4A2: 2 patients have deletions encompassing only NR4A2 gene and 1 patient has a deletion including NR4A2 and the first exon of GPD2. Our patients presented a neurodevelopmental disorder including language impairment, developmental delay, intellectual disability and/or autism spectrum disorder. We suggest that NR4A2 haploinsufficiency is implicated in neurodevelopmental disorder with high penetrance.
Collapse
Affiliation(s)
- J Lévy
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.,INSERM UMR1141, Paris Diderot University, AP-HP, Robert-Debré Hospital, Paris, France
| | - S Grotto
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France
| | - C Mignot
- Genetics Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.,Centre de Référence Déficience Intellectuelle de Causes Rares, GRC Université Pierre et Marie Curie « Déficience Intellectuelle et Autisme », Pitié-Salpêtrière Hospital, Paris, France
| | - A Maruani
- Child and Adolescent Psychiatry Department, Robert-Debré Hospital, AP-HP, Paris, France.,Neuroscience Department, Génétique Humaine et Fonction Cognitive Unit, Pasteur Institute, Paris, France
| | - A Delahaye-Duriez
- INSERM UMR1141, Paris Diderot University, AP-HP, Robert-Debré Hospital, Paris, France.,Department of Cytogenetics, Jean-Verdier Hospital, Paris 13 University, Embryology and Histology, AP-HP, Bondy, France.,Division of Brain Sciences, Imperial College Faculty of Medicine, London
| | - B Benzacken
- INSERM UMR1141, Paris Diderot University, AP-HP, Robert-Debré Hospital, Paris, France.,Department of Cytogenetics, Jean-Verdier Hospital, Paris 13 University, Embryology and Histology, AP-HP, Bondy, France
| | - B Keren
- Genetics Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - D Haye
- Genetics Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - J Xavier
- Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - M Heulin
- Unité de Diagnostic et d'Evaluation Pluriprofessionnelle de l'autisme et des troubles apparentés, Etablissement publique de santé de Ville-Evrard, Neuilly Sur Marne, France
| | - E Charles
- Unité de Diagnostic et d'Evaluation Pluriprofessionnelle de l'autisme et des troubles apparentés, Etablissement publique de santé de Ville-Evrard, Neuilly Sur Marne, France
| | - A Verloes
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.,INSERM UMR1141, Paris Diderot University, AP-HP, Robert-Debré Hospital, Paris, France
| | - C Dupont
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France
| | - E Pipiras
- INSERM UMR1141, Paris Diderot University, AP-HP, Robert-Debré Hospital, Paris, France.,Department of Cytogenetics, Jean-Verdier Hospital, Paris 13 University, Embryology and Histology, AP-HP, Bondy, France
| | - A-C Tabet
- Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.,Neuroscience Department, Génétique Humaine et Fonction Cognitive Unit, Pasteur Institute, Paris, France
| |
Collapse
|
42
|
Levy M, Martin L, Bursztejn A, Chiaverini C, Miquel J, Mahé E, Maruani A, Boralevi F. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol 2019; 182:1003-1006. [DOI: 10.1111/bjd.18369] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/21/2019] [Indexed: 11/30/2022]
Affiliation(s)
- M. Levy
- Paediatric Dermatology Unit, Children's Hospital Bordeaux University Hospital Bordeaux France
- Centre d'Investigation Clinique Pédiatrique 1401 Module Plurithématique Bordeaux University Bordeaux France
| | - L. Martin
- Department of Dermatology Angers University Hospital Angers France
| | - A.‐C. Bursztejn
- Department of Dermatology Nancy University Hospital Nancy France
| | - C. Chiaverini
- Department of Dermatology Nice University Hospital Nice France
| | - J. Miquel
- Paediatric Dermatology Unit Saint‐Pierre University Hospital Saint‐Pierre la Réunion France
| | - E. Mahé
- Department of Dermatology Hôpital Victor Dupouy Argenteuil France
| | - A. Maruani
- Department of Dermatology Tours University Hospital Tours France
| | - F. Boralevi
- Paediatric Dermatology Unit, Children's Hospital Bordeaux University Hospital Bordeaux France
- Centre d'Investigation Clinique Pédiatrique 1401 Module Plurithématique Bordeaux University Bordeaux France
| | | |
Collapse
|
43
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani AP, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance of severity scores for photographic assessment of hidradenitis suppurativa. Br J Dermatol 2019; 182:515-516. [PMID: 31494929 DOI: 10.1111/bjd.18480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- C Prouteau
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France
| | - M Dinulescu
- Department of Dermatology, CHU Rennes, F35000, Rennes, France
| | - E Oger
- EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France.,Pharmacovigilance, Pharmacoepidemiology and Drug Information Departments, PEPS Research Consortium, F35000, Rennes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | - C Laurent
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France
| | | | - A Dupuy
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France.,Pharmacovigilance, Pharmacoepidemiology and Drug Information Departments, PEPS Research Consortium, F35000, Rennes, France
| | | |
Collapse
|
44
|
Phan C, Beauchet A, Burztejn A, Severino‐Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj‐Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour J, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse A, Kupfer‐Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles‐Tsimaratos N, Mery‐Brossard L, Pallure V, Lons‐Danic D, Bouilly‐Auvray D, Beylot‐Barry M, Puzenat E, Aubin F, Mahé E. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1984-1992. [DOI: 10.1111/jdv.15579] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/27/2019] [Indexed: 02/06/2023]
|
45
|
Casassa E, Dreyfus I, Maruani A, Léauté-Labrèze C, Barbarot S, Aubert H, Croiset A, Bergeron A, Mazereeuw-Hautier J. Qualité de vie des enfants âgés de 11 à 15 ans atteints de malformation vasculaire à flux lent. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Leducq S, Gabeff R, Maruani A, Cornillier H. Inefficacité de la rapamycine (sirolimus) topique 1 % dans le traitement des cicatrices d’acné chéloïdiennes chez un adolescent. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Justine E, Welfringer A, Mallet S, Maruani A, Chiaverini C, Hubiche T, Boralevi F, Bourrat E. Ecthyma gangrenosum à Pseudomonas aeruginosa : une série de 14 cas pédiatriques. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Leducq S, Vrignaud S, Lorette G, Herbreteau D, Martin L, Maruani A. Traitement par rapamycine (sirolimus) topique 0,1 % d’une malformation lymphatique microkystique cutanée glutéale chez un jeune homme de 17 ans. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Leducq S, Maruani A, Kluger N, Samimi M. « Laser tag purpura » : une nouvelle cause de purpura d’effort. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Leducq S, Maruani A, Zaragoza J, Poiraud C, Tallegas M, Gabeff R. Proliférations lymphatiques cutanées bénignes acquises après radiothérapie et traitées par rapamycine topique 1 %. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|